Claude

People & Governance

Governance grade: C+ – Religare is mid-transition from a decade of mismanagement under erstwhile promoters to Burman Group control, with a reconstituted board of retired civil servants, no permanent CEO or MD, and heavy reliance on a CFO-led professional management team that has yet to prove itself.

The People Running This Company

The most striking feature of Religare's leadership is what is missing: there is no CEO or Managing Director at the holding company level. Dr. Rashmi Saluja, the former Executive Chairperson, was voted out by shareholders at the February 2025 AGM – her re-appointment resolution failed. The company is run day-to-day by CFO Pratul Gupta, supported by an Administrative Committee of senior managers. The Burman family, despite owning ~26% and being classified as promoters since February 2025, has not yet placed any family member on the REL board (proposed but pending regulatory approval as of Q3 FY26).

Key hires since the ownership change include Babu Rao (Group General Counsel, from Bajaj Finance), Indranil Choudhury (Group CHRO, from UTI Mutual Fund), and Vijay Goel (MD Religare Broking, from Motilal Oswal). The pace of leadership hiring is steady but not yet complete – senior roles across subsidiaries remain to be filled.

What They Get Paid

Compensation at the holding company level is modest. All directors are non-executive and receive only sitting fees (no salary, no ESOPs, no performance-linked pay). Independent Directors received INR 1,00,000 per Board/Audit/Risk meeting; non-independent directors INR 25,000 per meeting (revised downward in March 2025). The total board sitting fees for FY25 were approximately INR 1.5 crore – negligible relative to the INR 7,481 crore market cap. With no executive directors on the board currently, there is no executive compensation to scrutinize at the holding company level.

The former Executive Chairperson Dr. Rashmi Saluja's compensation details are not fully disclosed in available data, but the controversy surrounding her Care Health ESOPs (over 2% of CHIL equity) and her eventual ouster by shareholders suggest that pay alignment was a significant governance concern under the prior regime.

No ESOPs were granted under the REL ESOP Plan 2019 during FY2025.

Are They Aligned?

Ownership and Control: The Burman Group completed an open offer in February 2025, acquiring ~25.7% of REL. Their stake has inched up to 26.3% by Q3 FY26. On a fully diluted basis (after conversion of INR 1,500 crore warrants), promoters will hold ~29.75%. This is a meaningful but not controlling stake. FII holdings have been declining (from 18.3% in FY23 to 7.6% in Q3 FY26), while DII holdings rose and then fell. The public category dominates at ~57%.

Capital Infusion (Warrants): INR 1,500 crore preferential warrants at INR 235/share – split equally between promoter group (INR 750 crore) and other marquee investors (INR 750 crore). Of this, INR 410 crore received by Q3 FY26 (25% upfront + initial conversions). This is genuine capital commitment and a positive signal.

Insider Buying/Selling: No insider trading transactions are recorded in the data. No directors hold equity shares. The warrants represent the primary skin-in-the-game mechanism for the promoter group.

Dilution: The preferential warrants issue of 6.38 crore shares represents ~19.3% dilution to existing shareholders on a fully diluted basis. While the capital is needed for growth, the dilution is material.

Related Party Behavior: All related party transactions in FY25 were stated to be at arm's length and in ordinary course of business. No materially significant RPTs requiring shareholder approval were reported. This is a positive shift from the erstwhile promoter era, when fund siphoning through corporate loans and FD misappropriation at Lakshmi Vilas Bank (INR 750 crore, fully provisioned by RFL) were central governance failures.

Capital Allocation: Management is deploying proceeds as committed: INR 600 crore earmarked for Care Health, INR 200 crore for Broking, INR 250 crore for Housing Finance, INR 75 crore for REL debt repayment, INR 375 crore for general corporate purposes. The announced demerger of financial services businesses into RFL (to be listed by Q1 FY28) reflects a value-unlocking intent. However, the multi-step nature of restructuring (demerger now, potential CARE reverse merger later) creates execution uncertainty.

Skin-in-the-Game Score: 4/10. The Burman family has put up real capital via the open offer and warrants, which is positive. But the promoter stake is sub-30%, no board member or executive holds meaningful equity, and the warrants are still largely unexercised. The family's commitment will be tested by whether they increase their stake over time and whether the proposed board seats materialize.

Board Quality

Composition: As of the latest information, the board has 9 members: 6 independent and 3 promoter nominees. This exceeds SEBI requirements for independence ratio.

Strengths: The three promoter nominees (Mahalingam, Lamba, Gurumurthy) bring genuine BFSI expertise – insurance, capital markets, and banking/risk management respectively. This is a clear upgrade from the pre-Burman board.

Weaknesses: The four longer-tenured independent directors (Sinha, Tripathi, Madan, Dwivedi) are all retired civil servants (IPS, IAS, Indian Economic Service). While individually distinguished in public service, none has direct financial services operating experience. For a diversified financial services holding company, this is a significant gap. The board lacks a banking/lending specialist among its independents, and none of the independents has experience running a regulated financial institution.

The two newly appointed independents (Malla and Somani) partially address this – Malla sits on multiple listed boards with financial exposure, and Somani has industrial experience. But neither is a financial services operator.

Compliance Lapses of Note: Twenty board meetings were held in FY25 – an unusually high number reflecting the turbulent period of ownership transition, SEBI orders, and the ousting of Dr. Saluja. The SEBI interim order cum show cause notice (June 2024) alleging violation of SAST Regulations against REL and all its directors was a serious regulatory action, though the matter has been substantially addressed post the Burman takeover. The SFIO investigation (since Feb 2018) into erstwhile promoter-era misconduct remains ongoing.

The Verdict

Strongest positives: The Burman Group takeover represents a decisive break from the disastrous erstwhile promoter era (fund siphoning, fraud tags, RBI corrective action). Real capital of INR 1,500 crore has been committed. Legacy issues at RFL (CAP removed, fraud tags quashed, debt-free) have been conclusively resolved. The demerger plan shows strategic intent to unlock value. The promoter nominees bring genuine BFSI expertise to the board.

Real concerns: The company has been without a CEO/MD for over a year. The independent board is dominated by retired civil servants with no financial services operating experience. The Burman family has not yet placed any family member directly on the board. The look-through promoter holding in Care Health (~18-19%) falls short of the 25% IRDAI requirement for promoter classification, creating structural uncertainty about the eventual reverse merger. Investor requests for Burman family to directly address shareholders have been deflected. The multi-step restructuring plan (demerger now, potential CARE simplification later) could take 2-3+ years to complete.

What would trigger an upgrade: Appointment of a credible CEO/MD at the holding company level, Burman family members joining the board, and successful execution of the first phase of demerger (RFL listing by Q1 FY28). An increase in promoter stake beyond 30% and commencement of RFL lending operations would further strengthen the case.

What would trigger a downgrade: Failure to appoint a CEO/MD within the next 2-3 quarters, delays in demerger execution, any governance issues at subsidiaries, or Burman family signaling reduced commitment (e.g., not converting remaining warrants).